Jerrell Shelton: As I said during our last quarter’s call, I think that the development of this industry is similar to biologics. And if you look at biologics in the way it has and butters in the beginning and then leveled out and everyone today would want to be in biologics that’s in the pharmaceutical business. It’s a fantastic business and a larger business. And we’re on the same track. We’re in the beginning phases of the development of this industry. We’re developing solutions to answer questions in this industry, to answer needs in this industry and to help it propel and move forward. And we think we’re on the same track as biologics, if not better than that track.
John Sourbeer: Got it. Thanks for taking the questions.
Operator: Your next question comes from Jacob Johnson from Stephens. Your line is now open.
Jacob Johnson: Hey, thanks. Good evening. Congrats on the quarter. Thanks for taking the question. Maybe not to belabor the point, but just one more follow-up on the commercial revenue. Really strong growth. Dr. Sawicki, if I heard you correctly, it sounds like Sarepta had some portion of that. At the risk of asking a question you may not want to answer, but any way to tease out how much Sarepta was a contribution of growth this quarter?
Mark Sawicki: Yes. We don’t think to – break it out on a client-specific basis, but it was a meaningful contribution. I’ll leave it at that.
Jacob Johnson: Okay. That’s helpful. And then maybe a bigger picture question just on Integra-Cell, I think that’s a platform you guys have continued to build out over the last year. I’m just kind of curious where that stands on a revenue basis and as we head into next year, what’s the opportunity around that offering?
Jerrell Shelton: I’m going to start and let Dr. Sawicki, then take over. But the Integra-Cell has started during the last year, and it’s progressing. But these are – this is a novel solution for the cell and gene therapy industry, is something that’s needed in the industry. It will have to be not only the plants built out and finished, and Mark can comment on that. But then they will have to be validated and customers will then do their audits. But we have – we already are seeing demand coming in. This is a customer-driven endeavor. So we know it’s going to be successful. Mark?
Mark Sawicki: Yes, just to add on that. So the site in Houston is construction complete, we’re just going through all the validation activities as we speak. If the site in Belgium is nearly construction complete, will be running a couple of months behind the site in Houston. As Jerry mentioned, we’re already seeing very strong interest. We’ve already had a significant number of clients come through the facility even during construction. And we also have a – already have a robust pipeline as it relates to quotes that are evaluating it to be able to step into their clinical and commercial opportunities. So when the facilities come online in we believe that will be a very, very nice and quick uptake with that asset as it comes online.
Jacob Johnson: Got it. I will leave it there. Thanks for answering the questions.
Jerrell Shelton: Thank you, Jacob.
Operator: Your next question comes from Tejas Savant from Morgan Stanley. Your line is now open.
Unidentified Analyst: This is Yuko on for Tejas. Thank you for taking our questions. You talked about MVE demand starting to stabilize in China. Are you seeing effects of anticorruption initiatives still continuing in the region? And what do you think needs…
Jerrell Shelton: I’m sorry, you’re coming through on the phone very weak. I didn’t really get your questions in China.
Unidentified Analyst: Sorry about that, is that a little bit better?
Jerrell Shelton: Yes, that’s better, that’s better. Thank you.
Unidentified Analyst: You talked about MVE demand starting to stabilize in China. Are you seeing effects of anticorruption initiatives still continuing in the region? And what do you think needs to ultimately happen to begin seeing recovery of that market?
Jerrell Shelton: We’re not experts on the internal workings of China and what’s on the administration’s mind. But what we can tell you is that there has been some reserve as a result of the foreign corrupt practices. And so people are lying low. They don’t want to get caught in investigations and that sort of thing. So it is suppressing the market. And hopefully, that will open up very shortly. And President Xi is taking initiatives within the economy to stimulate it. But it’s not – it’s hard to predict exactly when that – when those initiatives will have some impact. We know one thing. We can’t discount China because it is a hot bed of activity for the life sciences and we intend to participate there.
Unidentified Analyst: Great. Thank you for that color. And then a separate follow-up. Could you elaborate more on the Tec4med Lifescience acquisition? How does their condition monitoring with AI differ from capabilities offered by Cryoport? And how do you envision incorporating their condition monitoring capabilities into Cryoport and SmartPack2 condition monitoring system?
Jerrell Shelton: I’ll start, and then I’m going to turn it over to Mark for a further comment. But Tec4med is truly a – our plan to acquisition with true strategic impact. The technologies that’s been developed by Tec4med over the last 8 years of its existence is, is fantastic technology. It’s complementary to much of the technology that we have within Cryoport or have underway at Cryoport, and it is – it will boost it. It will actually boost it. It will have synergistic value. It has a number of features that are going to have significant impact, certainly on Cryoport, and we think on the market in the future. So with that, I’ll turn it over to Mark to make further comments.
Mark Sawicki: Yes. Thanks, Jerry. Jerry is exactly right. It’s a very complementary product to our existing SmartPack2 condition monitoring platform and will provide us more depth with different service levels and competencies from obviously high-end real-time monitoring, as well as all the way down to a disposable data logs or 1-way or uni-directional transit packaging. So it’s a very complementary product for us, the product suite itself will dovetail very nicely into what we’ve built within our existing portfolio of services.
Jerrell Shelton: I’d just add just a couple of things. Just a couple of things on that. Look, you asked about AI. We’ve been using AI for a number of years. AI is an important technology. It’s advancing very quickly. They have that capability. And the other thing is, Tec4med is very communications friendly. It’s enhanced beyond anything on the market today, and we’ll be taking advantage of that. You’ll see it.
Unidentified Analyst: Great. Thank you.
Operator: Your next question comes from Yuan Zhi from B. Riley. Your line is now open.
